Nexien Biopharma Inc (PK:NXEN)
Business Focus: Pharmaceuticals
Feb 19, 2021 09:00 am ET
Nexien BioPharma, Inc. Engages CORE IR for Investor Relations, Public Relations and Shareholder Communications Services
Nexien BioPharma, Inc. ("Nexien"or the"Company") (OTCQB:NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems,...
Jul 16, 2020 01:48 pm ET
Nexien BioPharma, Inc. Has Been Issued a U.S. Patent for the Methods and Compositions for Treating Non-Dystrophic Myotonia and Myotonic Dystrophies Types 1 and 2
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that on July 7, 2020, it was issued a patent (US10,702,495) by the United States Patent and Trademark Office (USPTO).. This patent covers methods and compositions for treating patients having non-dystrophic myotonia and myotonic dystrophies (DM Type 1 and DM Type 2) with oral formulations of cannabidiol and tetrahydrocannabinol.
Jul 18, 2019 08:00 am ET
Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two co
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that it was granted Patent No. 238946 for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” by the Israeli Patent Office.
Mar 28, 2019 03:45 pm ET
Nexien BioPharma to Present at The MicroCap Conference Spring Investor Summit on Tuesday, April 2nd
DENVER, CO / ACCESSWIRE / March 28, 2019 / Nexien BioPharma, Inc. ("Nexien" or the "Company") (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development, and commercialization of advanced FDA Compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that its management will present at The MicroCap Conference Spring Investor Summit in New York City on Tuesday, April 2, 2019.
Mar 05, 2019 09:00 am ET
Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next
generation biopharmaceutical company focused on research, development
and commercialization of novel FDA-compliant cannabinoid pharmaceuticals
and related drug delivery systems, today announced that its patent
application No. 238946 for “Use of Cannabinoids and Terpenes for
Treatment of Organophosphate and Carbamate Toxicity” has been accepted
by the Israeli Patent Office. This application relates to pharmaceutical
formulation compositions and their method of use in which i
Feb 26, 2019 09:00 am ET
Nexien BioPharma to File Pre-IND Meeting Request with the FDA
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next
generation biopharmaceutical company focused on research, development
and commercialization of novel FDA-compliant cannabinoid pharmaceuticals
and related drug delivery systems, today announced encouraging results
of clinical observations of patient groups consisting of patients
suffering from non-dystrophic myotonia and myotonic dystrophies (DM)
type 1 and 2, indicating that specific cannabinoid formulations are
supportive in relief of myotonia and DM symptoms. Nexien inte
Feb 19, 2019 09:00 am ET
Nexien BioPharma Announces Executive and Business Updates
Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB:NXEN), a next
generation biopharmaceutical company focused on research, development
and commercialization of novel FDA-compliant cannabinoid pharmaceuticals
and related drug delivery systems, today announced executive and
business updates.
Dec 06, 2018 09:00 am ET
Nexien BioPharma Releases Letter to Shareholders Announcing 2019 Plans, 2018 Activities, and Work to Come From Acquisitions
via NEWMEDIAWIRE -- Dear Nexien BioPharma shareholders and friends, Since May 9, 2018, when Alain Bankier sent out the last shareholder letter, we have been very busy at Nexien BioPharma (“Nexien” or the “Company”) building the foundation for a...
Nov 28, 2018 09:00 am ET
Nexien BioPharma And Ivy League University Medical School Collaborate On Pre-Clinical Cannabinoid Studies
via NEWMEDIAWIRE -- Nexien BioPharma Inc. (OTC QB: NXEN) (“Nexien” or the “Company”) announced it is initiating a collaboration with the University Medical School (the “Medical School”) to perform pre-clinical studies using advanced parenteral...
Nov 26, 2018 08:00 am ET
Uptick Newswire's Stock Day Podcast Interviews Nexien BioPharma CEO, Alex Wasyl, to Discuss the Acquisition of CRX Bio Holdings and The Company’s Future in The Pharmaceutical Space
DENVER, CO / ACCESSWIRE / November 26, 2018 / Nexien BioPharma, Inc. (OTCQB: NXEN) (''Nexien'' or the ''Company'') is a US-based pharmaceutical company focused on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals. CEO, Alex Wasyl, joined Stock Day's Everett Jolly for the first time to discuss the recent acquisition of CRX Bio-Holdings by Nexien BioPharma, and the Company's future in the pharmaceutical industry.
Nov 06, 2018 09:42 am ET
Nexien BioPharma Advances in Clinical Use of a Cannabinoid-Based Formulation for the Treatment of Myotonic Dystrophies and Myotonia
DENVER, CO / ACCESSWIRE / November 6, 2018 / Nexien BioPharma Inc. (OTCQB: NXEN) ("Nexien" or the "Company") announced that it was initiating an investigation into the use of cannabinoid-based formulations for the treatment of patients suffering from Myotonic Dystrophy (DM) and Myotonia.
Oct 30, 2018 04:50 pm ET
Nexien BioPharma Acquires Princeton-Based CRx Bio and Announces Additions to Senior Management
CRx BIO is a researcher and developer of advanced cannabinoid-based therapeutic formulations
Oct 18, 2018 04:15 pm ET
NEXIEN BioPharma Inc. Announces Symbol Change to NXEN
DENVER, CO / ACCESSWIRE / October 18, 2018 / Nexien BioPharma Inc. (OTCQB: NXEN) (formerly Intiva BioPharma Inc.) (the "Company") today announced that effective as of October 19, 2018, the Company will trade on the OTC QB under the new stock symbol NXEN.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.